Literature DB >> 23164592

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.

Marius M Hoeper1, Doerte Huscher, H Ardeschir Ghofrani, Marion Delcroix, Oliver Distler, Christian Schweiger, Ekkehard Grunig, Gerd Staehler, Stephan Rosenkranz, Michael Halank, Matthias Held, Christian Grohé, Tobias J Lange, Juergen Behr, Hans Klose, Heinrike Wilkens, Arthur Filusch, Martin Germann, Ralf Ewert, Hans-Juergen Seyfarth, Karen M Olsson, Christian F Opitz, Sean P Gaine, C Dario Vizza, Anton Vonk-Noordegraaf, Harald Kaemmerer, J Simon R Gibbs, David Pittrow.   

Abstract

BACKGROUND: Originally reported to occur predominantly in younger women, idiopathic pulmonary arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to describe the characteristics of such patients and their survival under clinical practice conditions.
METHODS: Prospective registry in 28 centers in 6 European countries. Demographics, clinical characteristics, hemodynamics, treatment patterns and outcomes of younger (18-65 years) and elderly (>65 years) patients with newly diagnosed IPAH (incident cases only) were compared.
RESULTS: A total of 587 patients were eligible for analysis. The median (interquartile, [IQR]) age at diagnosis was 71 (16) years. Younger patients (n=209; median age, 54 [16] years) showed a female-to-male ratio of 2.3:1 whereas the gender ratio in elderly patients (n=378; median age, 75 [8] years) was almost even (1.2:1). Combinations of PAH drugs were widely used in both populations, albeit less frequently in older patients. Elderly patients were less likely to reach current treatment targets (6 min walking distance>400 m, functional class I or II). The survival rates 1, 2, and 3 years after the diagnosis of IPAH were lower in elderly patients, even when adjusted for age- and gender-matched survival tables of the general population (p=0.006 by log-rank analysis).
CONCLUSIONS: In countries with an aging population, IPAH is now frequently diagnosed in elderly patients. Compared to younger patients, elderly patients present with a balanced gender ratio and different clinical features, respond less well to medical therapy and have a higher age-adjusted mortality. Further characterization of these patients is required. CLINICAL TRIALS REGISTRATION: NCT01347216.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Elderly; Hemodynamics; Hypertension; Pulmonary; Survival

Mesh:

Year:  2012        PMID: 23164592     DOI: 10.1016/j.ijcard.2012.10.026

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  114 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Definition, epidemiology and registries of pulmonary hypertension.

Authors:  R Awdish; H Cajigas
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 3.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

4.  Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Daniele G Costa; Luiza V P Mendes; Ananssa M S Silva; Sabrina T Martinez; Margarete M Trachez; Valéria do M N Cunha; Tadeu L Montagnoli; Aline G M Fraga; Hao Wang; Leanne Groban; Carlos A M Fraga; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-08-10       Impact factor: 6.053

5.  Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Soundos Saleh; Corina Becker; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

6.  Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.

Authors:  Masaru Hatano; Hidehiro Yamada; Keiichi Fukuda; Koichiro Yoshioka; Masanori Funauchi; Masataka Kuwana; Masataka Sata; Mitsugu Taniguchi; Norifumi Nakanishi; Takefumi Saito; Tsutomu Saji; Shigetake Sasayama
Journal:  Heart Vessels       Date:  2014-07-16       Impact factor: 2.037

Review 7.  Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.

Authors:  Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2014-12-06       Impact factor: 5.460

8.  Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.

Authors:  Kari R Gillmeyer; Kyung M Lee; Qing Shao; Donald R Miller; Bradley A Maron; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2019-08

9.  More on idiopathic pulmonary arterial hypertension with a low diffusing capacity.

Authors:  Karen M Olsson; Jan Fuge; Katrin Meyer; Tobias Welte; Marius M Hoeper
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.